Galmed Pharmaceuticals Ltd
GLMD
Market Cap$1.91M
Close$
$1.06
186.6% upside
Current Fair Value
186.6% upsideUndervalued by 186.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.91 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 1.46 |
| Outstanding Shares | 5,045,324 |
| Avg 30 Day Volume | 273,838 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Galmed Pharmaceuticals Ltd
CEO: Allen Baharaff Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is ...